Serum and Bile Markers for Cholangiocarcinoma

Nehls, Oliver; Gregor, Michael; Klump, Bodo

doi:10.1055/s-2004-828891

Cited by 161 publications

(114 citation statements)

References 102 publications

(160 reference statements)

Supporting

Mentioning

108

Contrasting

Order By: Relevance

“…In a series of cholangiocarcinoma patients without PSC, the sensitivity of CA 19‐9 concentrations >100 U/mL in diagnosing cholangiocarcinoma was 53% 29. However, although CEA is also measured frequently, it has been reported to have unsatisfactory sensitivity and specificity for cholangiocarcinoma 30, 31. In the current study, elevated values of CEA were noted in 54.5% of mucinous cholangiocarcinoma patients.…”

Section: Discussioncontrasting

confidence: 42%

Mucinous cholangiocarcinoma: Clinicopathological features of the rarest type of cholangiocarcinoma

Sumiyoshi¹,

Shima²,

Okabayashi³

et al. 2017

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Mucinous cholangiocarcinoma is extremely rare and its clinicopathological features remain unclear. The present study aimed to analyze published data on mucinous cholangiocarcinoma. Medical databases were searched from 1980 to 2016, and clinicopathological data for 16 mucinous cholangiocarcinoma patients were obtained. Characteristic imaging findings, including hypovascular tumor with peripheral enhancement on computed tomography and angiography, extremely high intensity on T2‐weighted magnetic resonance images, intratumoral calcification and luminal communication between the tumor and bile duct on cholangiography, were noted. Mucinous cholangiocarcinoma was correctly diagnosed in one patient only, with some patients diagnosed as low‐malignant biliary cystic tumors preoperatively. Five cases were followed up after the first medical examination, and three of these were initially diagnosed as biliary cystadenoma or intraductal papillary neoplasm of the bile duct. All five tumors showed marked enlargement within 4 months of follow up. Macroscopically, the resected tumors were non‐cystic/solid in seven cases, and cystic in seven. Tumor diameter ranged from 5 cm to 22 cm, and mucoid cut surface, lobulation, lack of capsule and papillary growth were observed. Microscopically, co‐existing intraductal papillary neoplasm of the bile duct was noted in three of five patients with available data. Nine of 10 cases in whom the pathological stage was reported had advanced disease with lymph node and/or distant metastasis, and 5‐year survival was achieved in one microinvasive case only. Overall 1‐ and 3‐year survival rates were 60.1% and 40.1%, respectively. The possibility of mucinous cholangiocarcinoma should be considered when biliary cystic tumors are detected on imaging modalities, despite the rarity of this tumor.

show abstract

Section: Discussioncontrasting

confidence: 42%

Mucinous cholangiocarcinoma: Clinicopathological features of the rarest type of cholangiocarcinoma

Sumiyoshi¹,

Shima²,

Okabayashi³

et al. 2017

Annals of Gastroent Surgery

View full text Add to dashboard Cite

show abstract

“…Their use in CC was recently evaluated by Nehls et al, 6 who reviewed 11 studies with over 1,200 patients resulting in an average sensitivity of 71% and 51% and an average specificity of 78% and 88% for CA19.9 and CEA, respectively. The superior discriminatory power of CEA is noted both in this study and in the literature.…”

Section: Discussionmentioning

confidence: 99%

“…Nonparametric univariate analysis of these peaks revealed that 14 were differentially expressed (P Ͻ .05): 4 were upregulated (m/z 9,760, 10,096, 10,311, and 11,664) and 10 were downregulated (m/z 5,078, 5,734,5,933,6,105,6,632,7,939,8,468,8,691,8,905, and 16,089) in the cancer subgroup. The single most significant peak with highest discriminatory power was at m/z 10,311 and was upregulated in the cancer group (P Ͻ .001; ROC AUC 0.89) (Fig.…”

Section: Tissue Groupmentioning

confidence: 99%

See 1 more Smart Citation

Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture

et al. 2006

View full text Add to dashboard Cite

Proteomic techniques promise to improve the diagnosis of cholangiocarcinoma (CC) in both tissue and serum as histological diagnosis and existing serum markers exhibit poor sensitivities. We explored the use of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to identify potential protein biomarkers of CC. Twenty-two resected CC samples were compared with adjacent noninvolved bile duct tissue. Serum from patients with CC (n ‫؍‬ 20) was compared with patients with benign disease (n ‫؍‬ 20), and healthy volunteers (n ‫؍‬ 25). Samples were analyzed on hydrophobic protein chips via SELDI-TOF MS, and classification models were developed using logistic regression and cross-validation analysis. Univariate analysis revealed 14 individual peaks differentially expressed between CC and bile duct tissue, 4 peaks between CC and benign disease, and 12 peaks between CC and sera of healthy volunteers. The 4,462 mass-to-charge serum peak had superior discriminatory ability to carbohydrate antigen 19.9 (CA19.9) and carcinoembryonic antigen ( C holangiocarcinoma (CC) is a rare but devastating neoplasm that accounts for 3% of all gastrointestinal cancers and 15% of all primary liver cancers worldwide. 1 Five thousand new cases are diagnosed on average per year in the United States, and the incidence is rising. 2 Northeast Thailand sees the highest incidence, with 96 cases per 100,000. 1 Surgical resection is the only current chance of cure, with no proven adjunctive therapy; however, this approach has a mortality rate of 5% to 10%. 3 Even with margin-free resection, 5-year survival figures only reach 20% to 40%. 3,4 Unresectable disease is usually fatal within 6 months to 1 year, and over one third of patients present at a stage too late for resection. 3 This confirms the need for earlier and more accurate diagnostic processes.At present, diagnosis of CC relies on imaging of the biliary tree with computed tomography or ultrasonography in the presence of high clinical suspicion. Tissue diagnostic confirmation is possible for intrahepatic tumors but is very difficult in more distal and more common (2/3 of cases) extrahepatic cases. These frequently present as a stricture of the common bile duct, which can be further characterized by means of endoscopic retrograde cholangio-pancreatography. 5

show abstract

“…13 In patients with PSC and CC, a wide range of sensitivity (38-89%) and specificity (50-98%) of CA 19-9 has been reported. 3,9 Although serum CA 19-9 is the mainstay marker for the diagnosis of biliopancreatic malignancies, a persistent elevation can also be observed in various benign diseases with no evidence of malignancy. 14 In view of these drawbacks of CA 19-9, other circulating markers have been evaluated for diagnosis and prognosis of biliary malignancy, either alone or as a part of a biomarker panel.…”

Section: Introductionmentioning

confidence: 99%

The Value of Molecular Biomarkers in Biliary Tract Cancer in the Era of Targeted Therapy

Anand

Purl²,

Dhar

2011

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Serum and Bile Markers for Cholangiocarcinoma

Cited by 161 publications

References 102 publications

Mucinous cholangiocarcinoma: Clinicopathological features of the rarest type of cholangiocarcinoma

Mucinous cholangiocarcinoma: Clinicopathological features of the rarest type of cholangiocarcinoma

Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture

The Value of Molecular Biomarkers in Biliary Tract Cancer in the Era of Targeted Therapy

Contact Info

Product

Resources

About